Infection risk with infliximab (Remicade) and adalimumab (Humira) is similar in pediatric inflammatory bowel disease

1. Among children with inflammatory bowel disease, there were no significant differences in serious or outpatient infection risk between initiating infliximab (Remicade) and adalimumab (Humira). Evidence Rating Level: 2 (Good) Study Rundown: Pediatric Inflammatory Bowel Disease (IBD) includes Crohn disease (CD), ulcerative colitis (UC), and IBD-unclassified (IBD-U), and its prevalence is…